SCHEDULE 13D/A: Broadwood Capital Boosts Stake in Oncocyte Corp Through $10.6 Million Private Placement and Registered Direct Offering

Broadwood Capital and its affiliates have significantly increased their beneficial ownership in Oncocyte Corp to 40.2% through a $10.6 million private placement and registered direct offering at $2.05 per share.

Summary

• Broadwood Partners, L.P., Broadwood Capital, Inc., and Neal C. Bradsher (collectively, the "Reporting Persons") have increased their beneficial ownership in Oncocyte Corp.
• As of February 6, 2025, the Reporting Persons collectively beneficially own 11,560,350 shares of Oncocyte Corp, representing 40.2% of the outstanding shares.
• This increase is primarily due to Broadwood Partners entering into two agreements on February 6, 2025: a PIPE Purchase Agreement to acquire 4,505,488 shares in a private placement, and an RD Purchase Agreement to acquire 660,207 shares in a registered direct offering.
• The combined total purchase price for these newly acquired shares is $10,589,674, at a price of $2.05 per share.
• Oncocyte Corp also entered into a Registration Rights Agreement, agreeing to file a registration statement for the resale of shares acquired in the private placement.
• The funds for these purchases came from Broadwood Partners' working capital and Mr. Bradsher's personal funds, with no borrowed funds used for the direct purchase of shares.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. A significant capital infusion and increased stake by a major investor like Broadwood Capital signals confidence in Oncocyte Corp's future. However, the dilution for existing shareholders and the potential for activist investor actions temper the overall positivity.

Positives

• Significant capital infusion for Oncocyte Corp totaling $10,589,674, which can support operations, research, and development.
• Strong vote of confidence from a major existing investor (Broadwood Capital) by increasing its stake to 40.2%, signaling belief in the company's future.
• The private placement and registered direct offering structure allows the company to raise capital directly from a known investor, potentially reducing market volatility associated with broader public offerings.
• The Registration Rights Agreement facilitates future liquidity for Broadwood Partners, which can be a positive for the investor.

Negatives

• The issuance of new shares (4,505,488 in PIPE and 660,207 in RD offering) will result in dilution for existing shareholders not participating in the offering.
• Broadwood Capital's significant ownership (40.2%) gives them substantial influence over the company's strategic direction and corporate governance, which could be perceived negatively by other shareholders if their interests diverge.

Risks

• Market Conditions: The Reporting Persons reserve the right to effect future transactions (buy/sell shares) based on market conditions, which could impact share price volatility.
• Shareholder Value Maximization: While the Reporting Persons aim to maximize shareholder value, their specific strategies or recommendations might not align with all shareholders' interests.
• Dilution: Future capital raises or share issuances could lead to further dilution for existing shareholders.
• Regulatory Compliance: Future transactions by the Reporting Persons must comply with applicable securities laws, which could impose restrictions or delays.

Future Outlook

The Reporting Persons acquired their shares for investment purposes and reserve the right to adjust their holdings based on market conditions. They intend to continue engaging with Oncocyte Corp's management, board, and other shareholders to explore alternatives for maximizing shareholder value over time. They also reserve the right to act in concert with other shareholders or recommend courses of action to the company's stakeholders.

Industry Context

This filing indicates a significant capital injection into Oncocyte Corp, a company operating in the biotechnology and diagnostics sector. Such investments from major shareholders like Broadwood Capital are common in the biotech industry, where companies often require substantial funding for research, development, and commercialization of diagnostic products. The increased stake by a prominent investment firm suggests a belief in the long-term potential of Oncocyte's technology or market position, which could be a positive signal within the competitive diagnostics landscape.

Stakeholder Impact

• Shareholders: Existing shareholders face dilution from the issuance of new shares but benefit from the capital infusion and the vote of confidence from a major investor. Broadwood Capital's increased influence could impact future strategic decisions.
• Company (Oncocyte Corp): Receives over $10.5 million in capital, strengthening its financial position for operations and growth initiatives.
• Broadwood Capital: Increases its strategic stake and influence in Oncocyte Corp, aligning its investment with potential long-term value creation.

Next Steps

• Oncocyte Corp is expected to file a registration statement for the resale of shares acquired by Broadwood Partners pursuant to the PIPE Purchase Agreement.
• The Reporting Persons may continue to engage with Oncocyte Corp's management, board, and other significant shareholders regarding strategies to maximize shareholder value.
• The Reporting Persons reserve the right to adjust their holdings in Oncocyte Corp through open-market or privately negotiated transactions, subject to market conditions and applicable securities laws.
• The Reporting Persons may act in concert with other shareholders or recommend courses of action to the Issuer's stakeholders.

Key Dates

Recommendation

Keywords

Oncocyte Corp, Broadwood Capital, Schedule 13D/A, SEC filing, private placement, registered direct offering, share acquisition, beneficial ownership, investment, biotechnology, diagnostics, capital raise, shareholder stake